Trials / Recruiting
RecruitingNCT06305663
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 418 (estimated)
- Sponsor
- Bausch & Lomb Incorporated · Industry
- Sex
- All
- Age
- 8 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Detailed description
A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic) | Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic) |
| DEVICE | CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens | CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens |
Timeline
- Start date
- 2024-03-29
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
- First posted
- 2024-03-12
- Last updated
- 2025-06-15
Locations
11 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06305663. Inclusion in this directory is not an endorsement.